Importantly, promoting NRF2 activity through GSK3 inhibition already showed promising effects in AD [133,134,135] and PD [136,137], and therefore pave the way to potential treatments for oxidative stress-related retinal diseases. Here, NFE2L2 is linked to Abnormal retinal morphology.